LAS VEGAS, March 3, 2022 /PRNewswire/ -- The Actinic Keratosis Treatment Drugs produced by drug giants of the pharmaceuticals industry such as VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma), SR-T100 (G&E Herbal Biotechnology), GDC695 (Gage Development Company), and others are being assessed as potential therapies to be available in the Actinic Keratosis market. The launch of these topical therapies is anticipated to disrupt the existing market, with a remarkable safety efficacy profile for pipeline drugs such as VDA-1102.
DelveInsight's Actinic Keratosis Market report provides a thorough comprehension of the Actinic Keratosis historical and forecasted epidemiology and the Actinic Keratosis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Actinic Keratosis market report also proffers an analysis of the current Actinic Keratosis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Actinic Keratosis Market Research Report
- Several key pharmaceutical Actinic Keratosis companies, including Athenex, Almirall, Vidac Pharma, Promius Pharma, G&E Herbal Biotechnology, Gage Development Company, DFB Soria, DermAct Pharmaceutical, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and others are developing novel products to improve the Actinic Keratosis treatment outlook.
- Actinic Keratosis market to increase due to cost driver to patient's healthcare spending, improvement in disease management and diagnosis, and new treatment modalities. However, the growth of the Actinic Keratosis treatment market might be hampered due to the risk associated with the disease, socioeconomic burden, and patient awareness about indication.
- Klisyri, developed by Athenex, received FDA approval in December 2020 and was launched in the U.S. in February 2021.
- Major pharmaceutical and commercial cosmetic players are committed to developing the current pipeline to address the unmet needs and improvising the current treatment landscape, further bolstering the overall revenue generation in the next decade.
For further information on Market Impact by Therapies, visit: Actinic Keratosis Therapeutics Drugs Analysis
Actinic Keratosis, also referred to as solar keratosis, is a rough, scaly patch development on the skin from years of intense UV rays sun exposure often found on the face, lips, ears, forearms, scalp, neck, and back of the hands. The main Actinic Keratosis symptoms include rough, dry or scaly patch of skin, slightly raised patch or bump on the top layer of skin, itching, burning, bleeding or crusting.
DelveInsight estimates that the total Actinic Keratosis prevalent cases in 7MM in 2020 were 18,523,526 cases, out of which the highest prevalent cases of Actinic Keratosis were in the US, which accounted for approximately 62% of the total prevalent cases.
The Actinic Keratosis Market Insigts Report provides historical as well as forecasted epidemiological analysis segmented into:
- Total Prevalent Actinic Keratosis Cases
- Subtype Specific Prevalent cases of Actinic Keratosis
- Gender-Specific Actinic Keratosis Prevalence
Get a complete epidemiological segmentation breakdown @ Actinic Keratosis Epidemiological Analysis
Actinic Keratosis Treatment Market
The Actinic Keratosis therapeutics market is segmented widely into three main therapies that include the lesion directed destructive therapies (cryosurgery, curettage, laser, dermabrasion, surgery, etc.), field directed topical therapies (imiquimod, diclofenac sodium, ingenol mebutate, 5-fluorouracil, etc.), and Photodynamic therapies (Ameluz, Levulan Kerastick, Metvixia cream, Alacare, etc.). Besides this, certain off-label drugs are sometimes used for Actinic Keratosis Treatment, including Colchicine and Tretinoin.
Among topical therapies for Actinic Keratoses, 5-fluorouracil is the most widely used treatment, followed by Aldara (5% imiquimod), Zyclara (3.75% imiquimod), and Solaraze (3% diclofenac). The other filed-directed therapy option, i.e., Photodynamic Therapy (PDT), is also a growing therapy segment due to its non-invasive approach of treatment along with the emerging concept of daylight PDT; however, PDT accounts for the lowest Actinic Keratosis market share as compared to other therapies.
Klisyri or KX01 Ointment (KX2-391) is a novel, topical first-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. It represents a significant step forward in the Actinic Keratosis treatment due to its short treatment protocol and proven efficacy and safety profile. Klisyri, developed by Athenex, received FDA approval in December 2020, and was launched in the U.S. in February 2021.
Diclofenac 3% gel: Topical diclofenac sodium 3% gel is a nonsteroidal anti-inflammatory drug given FDA approval for keratosis treatment. It is an effective therapy when applied twice a day for three months. Its chief advantage is that it produces little-to-no inflammation and thus is tolerable.
The available therapeutics treatment options in Actinic Keratosis aim to reduce complications. The major players such as Vidac Pharma, Promius Pharma, G&E Herbal Biotechnology, Gage Development Company, and others are developing potential drugs to be available in the Actinic Keratosis market. The expected launch of these drugs shall fuel the Actinic Keratosis market growth during the forecast period, 2018-2030.
Actinic Keratosis Market Dynamics
Due to the high Actinic Keratosis prevalence and the looming threat of transformation to a cancerous lesion, prevention and timely treatment present opportunities to rein in health care costs. The success of novel therapies in the Actinic Keratosis treatment landscape can significantly impact treatment algorithms in the future. With an increasing array of Actinic Keratosis treatment modalities, dermatology providers who are engaged and educated in the development of therapies will have an exciting opportunity to tailor treatments to specific patient requirements for optimal efficacy and tolerability. Novel topical therapies are being developed which will aim to reduce Actinic Keratosis treatment time and improve tolerability. The success of these agents can significantly impact Actinic Keratosis treatment algorithms in the future.
The treatment modalities related to Actinic Keratosis are not cost-effective, especially in immunosuppressed patients. If the disease is not treated early or left untreated then it may progress to squamous cell carcinoma. Despite the advantages of field-directed therapies, agents often carry the limitations of prolonged treatment courses and high incidences of local skin reactions. The Actinic Keratosis treatment landscape comes hand in hand with associated potential risks posing complications and other health outcomes.
Scope of the Actinic Keratosis Market Analysis Report
- Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
- Study Period: 2018-2030
- Actinic Keratosis Markets Segmentation: By Geographies and By Actinic Keratosis Therapies (Historical and Forecasted, Current and Upcoming)
- Key Actinic Keratosis companies: Athenex, Almirall, Vidac Pharma, Promius Pharma, G&E Herbal Biotechnology, Gage Development Company, DFB Soria, DermAct Pharmaceutical, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and several others.
- Analysis: Comparative and conjoint analysis of Actinic Keratosis emerging therapies
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Actinic Keratosis Treatment Market
Table of Contents
1 | Actinic Keratosis Key Insights |
2 | Actinic Keratosis Report Introduction |
3 | Actinic Keratosis Market Overview at a Glance |
4 | Executive Summary of Actinic Keratosis |
5 | Actinic Keratosis Disease Background and Overview |
6 | Actinic Keratosis Epidemiology and Patient Population |
7 | Country Wise-Epidemiology of Actinic Keratosis |
7.1 | The United States |
7.2 | EU5 Countries |
7.2.1 | Germany |
7.2.2 | France |
7.2.3 | Italy |
7.2.4 | Spain |
7.2.5 | The United Kingdom |
7.3 | Japan |
8 | Organizations contributing towards Actinic Keratosis |
9 | Actinic Keratosis Case Reports |
10 | Actinic Keratosis Patient Journey |
11 | Actinic Keratosis Marketed Therapies |
12 | Actinic Keratosis Emerging Therapies |
13 | Actinic Keratosis 7MM Market Analysis |
13.1 | The United States Actinic Keratosis Market Size |
13.2 | EU-5 Actinic Keratosis Market Size |
13.2.1 | Germany Market Size |
13.2.2 | France Market Size |
13.2.3 | Italy Market Size |
13.2.4 | Spain Market Size |
13.2.5 | The United Kingdom Market Size |
13.2.3 | Japan Actinic Keratosis Market Size |
14 | Actinic Keratosis Market Drivers |
15 | Actinic Keratosis Market Barriers |
16 | Actinic Keratosis SWOT Analysis |
17 | Actinic Keratosis Unmet Needs |
18 | Actinic Keratosis KOL Views |
19 | Appendix |
20 | DelveInsight Capabilities |
21 | Disclaimer |
22 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Actinic Keratosis Treatment and Diagnostics
View Other Reports
Actinic Keratosis Pipeline Insights, 2022
Actinic Keratosis Pipeline Insights, 2022 report by DelveInsight outlines comprehensive insights of present clinical development scenario, growth prospects, and key Actinic Keratosis companies such as DFB Soria, DermAct Pharmaceutical, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and others.
Actinic Keratosis Epidemiology
DelveInsight's Actinic Keratosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.
Actinic Keratosis Global API Manufacturers, Marketed and Phase III Drugs Landscape
Actinic Keratosis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Actinic Keratosis.
Seborrhoeic Dermatitis Pipeline
DelveInsight's, "Seborrhoeic Dermatitis Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Seborrhoeic Dermatitis companies such as Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S, Amorepacific, and others.
Genital Warts Pipeline
DelveInsight's, "Genital Warts Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Genital Warts companies such as ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc, Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis, and others.
Browse Blog Posts
- Key Skin Cancer Pharma Companies Expanding their Treatment Segment
- Analyzing Dermatology Gene Therapies and Key Dermatology Companies Associated
- Development of Gene Therapies in Dermatology
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
